Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00136292

Enrollment

Registered

2005-08-29

Start date

2005-08-24

Completion date

2006-08-09

Last updated

2020-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-positive Bacterial Infections

Keywords

Gram-Positive Infection

Brief summary

The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. The tolerability of a single dose of daptomycin in these patients will also be assessed.

Interventions

DRUGdaptomycin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 17 Years

Healthy volunteers

Inclusion criteria

* 2-17 years old * Suspected or diagnosed gram-positive infection for which the patient is receiving standard antibiotic therapy * Clinically stable with no evidence of hemodynamic instability in the 72 hour window prior to enrollment, and no history or evidence of renal or hepatic compromise, or clinically significant alterations in fluid/electrolyte homeostasis * Creatinine clearance (CLcr) ≥ 80 ml/min/1.73 m2 as determined by the Schwartz equation * Creatine phosphokinase (CPK) levels within normal limits

Exclusion criteria

* Known allergy to daptomycin * History of clinically significant cardiovascular, renal, hepatic, pulmonary (well-controlled asthma is acceptable), gastrointestinal, endocrine, hematologic, or autoimmune disease * Pneumonia as sole gram-positive infection * Use of HMG-CoA reductase inhibitors or other systemic anti-hyperlipidemic agents within 7 days prior to study drug administration and expected use through 3 days post-dose * Clinically significant abnormal laboratory test results (including electrocardiograms \[ECGs\]), as determined by Investigator * Body mass index (BMI) that is outside of the 5th to 95th percentile for age * History (personal or 1st degree relative) of clinically significant muscular disease, nervous system, seizure or psychiatric disorder * Expected intramuscular (IM) injection within 3 days following dosing * Expected surgical procedure(s) within 3 days following dosing * Unexplained muscular weakness * Rhabdomyolysis, myositis or septic shock

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic	—

Secondary

Measure	Time frame
Tolerability	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026